Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

O eixo AgRP e GH/IGF-1 em crianças

22 de setembro de 2026 atualizado por: Pamela U. Freda, Columbia University

Peptídeo relacionado a Agouti (AgRP) e o eixo GH/IGF-1 em crianças

Recent data support the existence of a GH-Agouti-related peptide (AgRP) axis. The neuropeptide AgRP promotes food intake and has important effects on energy homeostasis. Recent evidence suggest that GH stimulates AgRP and AgRP may mediate some of GH's important nutritional and metabolic effects. main goals of this project are to characterize, for the first time, plasma levels of AgRP in children and to determine how these relate to GH and IGF-1 levels, age, body composition, clinical and other endocrine parameters. To accomplish this, we will conduct two studies, one being a cross-sectional study that will measure AgRP levels in 140 healthy children ages 5-17 and the second being a prospective study that will measure the change in plasma AgRP levels in response to GH treatment in 16 children who receive this as part of their clinical care for GH deficiency or short stature.

Visão geral do estudo

Status

Ainda não está recrutando

Descrição detalhada

Protocol 1 This will be a cross-sectional study in 140 healthy children. Participation will include one visit that will take place between 8-9 am and after a fast from midnight the night before.

Procedures at the visit will include:

  1. Review of medical history
  2. Anthropometrics measurements: Weight, height, waist and hip circumferences.
  3. Collection of information from medical record including growth records and physical examination findings including features relevant to pubertal stage in all children and onset of menses in females.
  4. Assessment of pubertal status and Tanner stage based on physical examination.
  5. Collection of information on diet, activity level and sleep.
  6. Blood Sampling: venous blood will be sampled from a peripheral vein for measurement of AgRP, GH, IGF-1, leptin, SOb-R, triglycerides, insulin, glucose, testosterone(males), estradiol(females), DHEAS and cortisol levels. Insulin and glucose levels will be used to assess insulin resistance by HOMA & QUICKI.

Protocol 2 This will be a prospective study in 16 children who will be studied before and at 4 time points (1 week, 2 weeks, 1 month and 2 months) after starting GH treatment as part of their clinical care. This protocol will study subjects Groups 2 and 3. Growth hormone will not be prescribed as part of this study. Children will be treated clinically with GH as prescribed by their Pediatric Endocrinologist for FDA approved indications and according to standard guidelines for dosing for treatment of GH deficiency in children.

Each visit that will take place between 8-9 am and after a fast from midnight the night before.

Procedures at each visit will include:

  1. Review of medical history
  2. Anthropometrics measurements: Weight, height, waist and hip circumferences, skinfold thicknesses.
  3. Collection of information from medical record including growth records and physical examination findings including features relevant to pubertal stage in all children and onset of menses in females. GH dose and compliance will be recorded at follow up visits.
  4. Collection of information on diet, activity level and sleep.
  5. Blood Sampling: Venous blood will be sampled at a peripheral vein for:

Baseline (pre-GH treatment): measurement of AgRP, GH, IGF-1, IGFBP-3, leptin, SOb-R, triglycerides, insulin and glucose, testosterone(males), estradiol(females), DHEAS and cortisol levels.

Follow up visits on growth hormone: measurement of AgRP, IGF-1, IGFBP-3, leptin, SOb-R, triglycerides, insulin, glucose and cortisol levels.

Insulin and glucose levels will be used to assess insulin resistance by HOMA & QUICKI.

Tipo de estudo

Observacional

Inscrição (Estimado)

156

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Estude backup de contato

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

5 anos a 17 anos (Filho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Healthy children: 140 healthy children (70 females and 70 males) between the ages of 5-17 yr. will be studied; 7-8 children per year of this age range will be studied. They will be representative of the diverse racial and ethnic mix of children who receive their medical care at our medical center.Children will be recruited from among the healthy children visiting primary care Pediatricians at our medical center.

GH deficient and idiopathic short stature children: 16 children (8 males, 8 females) between the ages of 5 - 9 yr. who are pre-pubertal and who plan to start GH treatment for isolated GH deficiency or idiopathic short stature. They will be representative of the diverse racial and ethnic mix of our hospital's patient population.

Descrição

Healthy children

Inclusion Criteria:

  1. Ambulatory male and female children aged 5-17 years
  2. Normal weight at birth
  3. Height between the 3rd and 99th percentiles of the mean as per the CDC growth percentiles.

Exclusion Criteria:

  1. Genetic defects, chronic illnesses.
  2. Current prescription medication use
  3. Use of glucocorticoids, thyroid hormone or medications that may affect the GH-IGF-1 axis within 6 months of study entry.

Children with GH deficiency:

Inclusion Criteria:

  1. Ambulatory male and female children aged 5-9 years who are prepubertal
  2. Normal weight at birth
  3. Growth failure
  4. Peak GH response to 2 GH stimulation tests < 10 ng/ml
  5. Normal renal and liver function

Exclusion criteria:

  1. Multiple pituitary hormone deficiencies,
  2. GH deficiency or poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.
  3. History of diabetes or malignancy
  4. Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.

Children with idiopathic Short Stature:

Inclusion Criteria:

  1. Ambulatory male and female children aged 5-9 years who are prepubertal
  2. Normal weight at birth
  3. Height >2.25 SD below mean for age
  4. Peak GH response to 2 stimulation tests >10 ng/ml or normal IGF-1 and IGFBP-3 levels
  5. No prior supplemental growth hormone exposure
  6. Normal renal and liver function

Exclusion criteria:

  1. Poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.
  2. History of diabetes or malignancy
  3. Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: COHORT
  • Perspectivas de Tempo: CROSS_SECTIONAL

Coortes e Intervenções

Grupo / Coorte
Group 1: Healthy children

140 healthy children (70 females and 70 males) between the ages of 5-17 yr. will be studied; 7-8 children per year of this age range will be studied. They will be representative of the diverse racial and ethnic mix of children who receive their medical care at our medical center.

Inclusion Criteria:

  1. Ambulatory male and female children aged 5-17 years
  2. Normal weight at birth
  3. Height between the 3rd and 99th percentiles of the mean as per the CDC growth percentiles.

Exclusion Criteria:

  1. Genetic defects, chronic illnesses.
  2. Current prescription medication use
  3. Use of glucocorticoids, thyroid hormone or medications that may affect the GH-IGF-1 axis within 6 months of study entry.
Group 2: Children with GH deficiency

16 children (8 males, 8 females) between the ages of 5 - 9 yr. who are pre-pubertal and who plan to start GH treatment for isolated GH deficiency or idiopathic short stature.

They will be representative of the diverse racial and ethnic mix of our hospital's patient population.

GH deficiency:

Inclusion Criteria:

  1. Ambulatory male and female children aged 5-9 years who are prepubertal
  2. Normal weight at birth
  3. Growth failure
  4. Peak GH response to 2 GH stimulation tests < 10 ng/ml
  5. Normal renal and liver function

Exclusion criteria:

  1. Multiple pituitary hormone deficiencies,
  2. GH deficiency or poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.
  3. History of diabetes or malignancy
  4. Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.
Group 3: Children with short stature

Idiopathic Short Stature:

Inclusion Criteria:

  1. Ambulatory male and female children aged 5-9 years who are prepubertal
  2. Normal weight at birth
  3. Height >2.25 SD below mean for age
  4. Peak GH response to 2 stimulation tests >10 ng/ml or normal IGF-1 and IGFBP-3 levels
  5. No prior supplemental growth hormone exposure
  6. Normal renal and liver function

Exclusion criteria:

  1. Poor growth associated with any acute or chronic medical condition such as renal disease or Turner's syndrome.
  2. History of diabetes or malignancy
  3. Use of glucocorticoids or medications known to affect the GH-IGF-1 axis within 6 months of study entry.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Protocol 1: Correlation of Plasma AgRP levels with IGF-1 levels
Prazo: Baseline (cross-sectional at single time point, no intervention)

Plasma AgRP levels correlation with IGF-1 levels Protocol 1: Correlation of Plasma AgRP levels with IGF-1 levels

Baseline (cross-sectional at single time point, no intervention)
Protocol 2: Change in plasma AgRP levels with GH therapy
Prazo: baseline to 2 months

Change in plasma AgRP levels from pre-GH therapy to post-GH therapy

baseline to 2 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Protocol 1: Correlation of plasma AgRP levels with age
Prazo: Baseline (cross-sectional testing at one time point, no intervention)

Correlation of plasma AgRP levels with age

Baseline (cross-sectional testing at one time point, no intervention)
Protocol 1: Correlation of plasma AgRP levels with leptin levels
Prazo: Baseline (cross-sectional testing at one time point, no intervention)

Correlation of plasma AgRP levels with leptin levels

Baseline (cross-sectional testing at one time point, no intervention)
Protocol 1: Correlation of plasma AgRP with percent body fat (determined from skinfold thickness)
Prazo: Baseline (cross-sectional testing at one time point, no intervention)

Correlation of plasma AgRP with percent body fat (determined from skinfold thickness)

Baseline (cross-sectional testing at one time point, no intervention)
Protocol 2: Change in AgRP levels correlation with change in IGF-1 levels
Prazo: Baseline to 2 months

Correlation of change in AgRP levels with change in IGF-1 levels from baseline to 2 months of GH therapy

Baseline to 2 months
Protocol 2: Change in AgRP level correlation with pre-treatment leptin levels
Prazo: Baseline to 2 months

Correlation of change in AgRP level from baseline to 2 months of GH therapy with pre-treatment leptin levels

Baseline to 2 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

10 de junho de 2027

Conclusão Primária (Estimado)

31 de dezembro de 2027

Conclusão do estudo (Estimado)

31 de dezembro de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

30 de novembro de 2022

Enviado pela primeira vez que atendeu aos critérios de CQ

8 de dezembro de 2022

Primeira postagem (Real)

9 de dezembro de 2022

Atualizações de registro de estudo

Última Atualização Postada (Real)

25 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

22 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever